Selected – 2020

Network of Centres of Excellence in Neurodegeneration (CoEN): Pathfinder IV Call 2019

The ANR joins the Network of Centres of Excellence in Neurodegeneration (CoEN) to launch a Transnational Call aimed at supporting transnational research collaborations in the field of neurodegenerative disease. Six countries from the European Research Area and abroad launch this joint call for proposals: Canada, France, Germany, Italy, Spain and United Kingdom.

CoEN seeks to build productive links between research groups within recognised centres of excellence (CoEs) in neurodegeneration. The objective of this call is to stimulate new and unconventional approaches and creative solutions to the challenges of neurodegeneration research by undertaking high-risk / high-payoff research.

CoEN scope is broad covering basic, clinical, health services, policies and social aspects of neurodegenerative diseases. Projects may include studies to illuminate the understanding of neurodegenerative mechanisms, or create technological advances to support novel diagnostic or therapeutic approaches. Connectivity with research in related areas, such as inflammation and sensory neuroscience, or vascular and mental health is encouraged, as is outreach to experts in the fields of physical and computational science and industry when properly justified by the proposal.

The present call will finance research addressing the following neurodegenerative diseases: Alzheimer’s disease (AD) and other dementias, Huntington’s Disease (HD), Parkinson’s disease (PD) and PD‐related disorders, Multiple Sclerosis, Motor neurone diseases (MND), Prion disease, Spinocerebellar ataxia (SCA) and Spinal muscular atrophy (SMA).

The call will only fund research which has the potential to move the field forward significantly. Incremental studies, embellishment of known mechanisms or biomarker identification from known pathways will be ineligible.

Applications are restricted to joint proposals from investigators within identified CoEs (a list of identified CoEs and eligible institutions for partner countries is available on CoEN website – see below).

Only joint transnational research projects will be funded. Each proposal must involve researchers from at least two CoEs (or eligible institutions) from different countries. More than one CoE may be involved within any single country. Each project should identify a Lead Principal Applicant and one Principal Applicant from each participating country. An investigator may not be a Principal Applicant on more than one project submitted through this call.

Funding will be awarded for a maximum of two years and is expected to start beginning 2020.

Opening : 2019-06-19 at 14:00 CEST
Application Deadline : 2019-11-04 at 17:00 CET


Applications must be submitted by email as a PDF copy of the application form to: coen(at)

All proposals must be submitted by the lead applicant and should be accompanied by letters of support from the respective CoE directors. These letters should verify the eligibility of researchers in each of the partner CoEs and highlight the innovative aspects of the proposal.

Whilst applications will be submitted jointly by research groups from several countries, individual groups will be funded by the individual funding organisation of their country/region. French applicants are therefore subject to the ANR eligibility criteria and the funding of French applicants will be regulated according to the ANR rules. Please read carefully the “Appendix for French participants” (see above).


Secretariat of the COEN Oversight Group:


ANR contact:

Dr. Sheyla Mejia-Gervacio/Dr. Kiri Couchman


Consult the upcoming and current calls of the portal

The portal centralises all information on calls for proposals and calls for applications from ADEME, ANR, Inserm including ANRS, Anses and INCa. It provides a simplified access to upcoming and ongoing calls, giving a greater visibility to funding opportunities. Following their closing date, the calls remain published for a few months.


Sign up for the latest news:
Subscribe to our newsletter